Publicaciones en las que colabora con Antonio Gómez Caamaño (11)

2022

  1. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

    World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466

2019

  1. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672

  2. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology

    Clinical and Translational Oncology, Vol. 21, Núm. 4, pp. 420-432

  3. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study

    Radiotherapy and Oncology, Vol. 135, pp. 13-18

  4. Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes

    Clinical and Translational Oncology, Vol. 21, Núm. 8, pp. 1044-1051

2018

  1. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database

    Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 193-200

  2. Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 5, pp. 302-314

2016

  1. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272]

    Reports of Practical Oncology and Radiotherapy

  2. The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 1026-1033

2015

  1. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

    Reports of Practical Oncology and Radiotherapy, Vol. 20, Núm. 4, pp. 259-272

2013

  1. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572